Related Experiment Video
Updated: Dec 2, 2025
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Turning Up the Heat on the Pancreatic Tumor Microenvironment by Epigenetic Priming
1Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana. knephew@indiana.edu.
Abstract:
The study by Gonda and colleagues, in this issue of Cancer Research, represents the first combinatorial approach based on epigenetic therapy priming to overcome resistance to immunotherapy in pancreatic cancer. The authors show that treatment with a DNA hypomethylating agent causes profound changes in the pancreatic cancer microenvironment, including increased numbers of tumor-infiltrating T cells, elevated IFN signaling, and immune checkpoint expression, as well as increased antigen presentation in tumor cells. Accordingly, they show that the combination of decitabine plus immune checkpoint blockade effectively restores antitumor immunity and results in a significant survival benefit in a widely accepted mouse model of pancreatic cancer. The study provides evidence for a new therapeutic approach for pancreatic cancer having antitumor efficacy through modulation of the immune suppressive microenvironment, leading to an increased response to immune checkpoint inhibitors. As the incidence of pancreatic cancer continues to increase, new treatment strategies for this devastating disease are urgently needed. Gonda and colleagues provide preclinical proof of concept for a new therapeutic strategy and address an unmet need for this difficult to treat disease.See related article by Gonda et al., p. 4754.
Insights
Epigenetic therapy with decitabine primes pancreatic tumors for immunotherapy. This combination overcomes resistance, enhancing T cell activity and improving survival in preclinical models.
Area of Science:
- Oncology
- Immunology
- Epigenetics
Background:
- Pancreatic cancer exhibits high resistance to immunotherapy.
- Novel therapeutic strategies are urgently needed due to increasing incidence and poor prognosis.
Purpose of the Study:
- To investigate a combinatorial epigenetic therapy approach to overcome immunotherapy resistance in pancreatic cancer.
- To evaluate the efficacy of decitabine combined with immune checkpoint blockade.
Main Methods:
- Treatment with a DNA hypomethylating agent (decitabine).
- Combination therapy with decitabine and immune checkpoint blockade.
- Assessment of pancreatic cancer microenvironment changes, including T cell infiltration and antigen presentation.
- Evaluation of antitumor immunity and survival in a pancreatic cancer mouse model.
Main Results:
- Decitabine treatment profoundly altered the tumor microenvironment.
- Increased tumor-infiltrating T cells, IFN signaling, and antigen presentation were observed.
- The combination therapy restored antitumor immunity and significantly improved survival.
Conclusions:
- Epigenetic therapy priming with decitabine can overcome resistance to immunotherapy in pancreatic cancer.
- This combinatorial approach modulates the immune suppressive microenvironment, enhancing response to immune checkpoint inhibitors.
- Provides preclinical proof of concept for a novel therapeutic strategy for pancreatic cancer.
Related Concept Videos
01:19Psychoneuroimmunology: Diabetes and Cancer
02:17The Tumor Microenvironment